6,258 Shares of Cencora, Inc. $COR Purchased by Waycross Partners LLC

Waycross Partners LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,258 shares of the company’s stock, valued at approximately $1,879,000.

Other hedge funds have also recently modified their holdings of the company. Deutsche Bank AG bought a new stake in shares of Cencora during the 2nd quarter worth approximately $286,673,000. SEB Asset Management AB bought a new position in Cencora in the 1st quarter valued at $134,139,000. Wedge Capital Management L L P NC grew its position in Cencora by 31.0% in the 2nd quarter. Wedge Capital Management L L P NC now owns 105,614 shares of the company’s stock valued at $29,887,000 after acquiring an additional 24,968 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Cencora in the second quarter worth $841,000. Finally, Peachtree Investment Partners LLC purchased a new stake in Cencora in the second quarter worth $2,204,000. Institutional investors own 97.52% of the company’s stock.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat quarterly expectations, reporting EPS of $4.66 versus estimates of $4.58 and revenue of $88.35 billion versus $87.95 billion; revenue grew 5.5% year over year. The company also issued a stronger fiscal 2027 earnings outlook, reinforcing expectations for continued growth. Cencora stock enters fiscal 2027 with stronger earnings outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 from $388 and maintained an “outperform” rating, signaling confidence in potential upside.
• Positive Sentiment: Cencora raised its dividend, adding to its appeal for income-focused investors amid market uncertainty. Stocks that hiked dividends
• Neutral Sentiment: The company is realigning its corporate structure. The available report headline does not specify the changes or their expected financial impact. Cencora realigning corporate structure
• Negative Sentiment: Despite Cencora’s earnings beat, shares came under pressure after rival Cardinal Health reported results, prompting concern about relative performance and contributing to a short-term pullback. Cencora drops while rival Cardinal Health posts a beat

Cencora Stock Down 1.9%

NYSE:COR traded down $6.30 during mid-day trading on Friday, reaching $333.38. The company’s stock had a trading volume of 1,682,033 shares, compared to its average volume of 1,163,722. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a fifty day moving average of $325.07 and a 200-day moving average of $317.28. The firm has a market capitalization of $63.62 billion, a PE ratio of 18.60, a price-to-earnings-growth ratio of 1.73 and a beta of 0.58. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, beating analysts’ consensus estimates of $4.58 by $0.08. The business had revenue of $88.35 billion for the quarter, compared to the consensus estimate of $87.95 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.84 EPS. Equities research analysts forecast that Cencora, Inc. will post 19.58 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Friday, November 13th will be paid a dividend of $0.66 per share. This is a boost from Cencora’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, November 13th. Cencora’s payout ratio is 13.39%.

Analysts Set New Price Targets

COR has been the subject of several research analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a $330.00 target price on shares of Cencora in a research report on Tuesday, September 8th. Evercore restated an “outperform” rating and issued a $350.00 price target (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Bank of America raised their price target on shares of Cencora from $285.00 to $310.00 in a research note on Tuesday, July 21st. UBS Group decreased their price objective on shares of Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a report on Friday, October 16th. Finally, Morgan Stanley lifted their price objective on shares of Cencora from $346.00 to $377.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $368.73.

Insider Activity

In other news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.38% of the company’s stock.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally.